Butterfly Network (BFLY) Projected to Post Quarterly Earnings on Thursday

Butterfly Network (NYSE:BFLY) is expected to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.0353) per share and revenue of $28.37 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Butterfly Network (NYSE:BFLY) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. The firm had revenue of $32.61 million for the quarter, compared to analyst estimates of $29.16 million. Butterfly Network had a negative net margin of 66.74% and a negative return on equity of 33.99%. On average, analysts expect Butterfly Network to post ($0.18) EPS for the current fiscal year and ($0.14) EPS for the next fiscal year.

Butterfly Network Stock Performance

NYSE BFLY opened at $6.66 on Tuesday. Butterfly Network has a 1 year low of $1.90 and a 1 year high of $10.21. The business’s fifty day moving average is $8.21 and its two-hundred day moving average is $5.97. The stock has a market capitalization of $1.77 billion, a P/E ratio of -22.96 and a beta of 2.04.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on BFLY shares. Canaccord Genuity Group initiated coverage on Butterfly Network in a report on Monday, October 12th. They issued a “buy” rating and a $10.00 target price on the stock. TD Cowen reaffirmed a “buy” rating and set a $10.00 target price on shares of Butterfly Network in a report on Friday, September 11th. Needham & Company LLC started coverage on Butterfly Network in a research report on Tuesday, September 22nd. They issued a “buy” rating and a $10.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Butterfly Network in a research report on Monday, August 3rd. Finally, Evercore assumed coverage on Butterfly Network in a research note on Tuesday, September 29th. They issued an “outperform” rating and a $15.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.75.

Insiders Place Their Bets

In related news, insider Steve Cashman sold 140,112 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $7.30, for a total value of $1,022,817.60. Following the completion of the sale, the insider directly owned 1,490,295 shares of the company’s stock, valued at approximately $10,879,153.50. This represents a 8.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Louise Phanstiel acquired 115,200 shares of Butterfly Network stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of $8.68 per share, with a total value of $999,936.00. Following the completion of the purchase, the director owned 300,461 shares in the company, valued at approximately $2,608,001.48. This represents a 62.18% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 354,707 shares of company stock valued at $2,967,211 over the last quarter. 21.99% of the stock is owned by insiders.

Butterfly Network Company Profile

Butterfly Network, Inc develops portable medical imaging technology designed to make ultrasound more accessible across hospitals, clinics, emergency-care settings and other care environments. The company’s core products use a semiconductor-based ultrasound-on-chip platform, replacing conventional ultrasound systems’ large arrays of piezoelectric transducers with a compact, software-driven probe.

Its product portfolio includes the Butterfly iQ, iQ+, and iQ3 handheld ultrasound systems, which connect to compatible mobile devices and provide imaging across multiple clinical applications.